Research in cell lines suggests that inhibition of STAT3 activity in cancer cells could prevent or even reverse resistance to anti-cancer drugs [6] Meanwhile STAT2, a TF and downstream mediator of type I interferon (IFN-I) signaling, can either inhibit or enhance tumorigenesis, with its effects being dependent on the distinct microenvironment in each cancer type [7]. This evidence concerns the gene STAT3 and cancer.